cbdMD, Inc.
Business
cbdMD, Inc. is a consumer wellness company that develops, manufactures, markets, and sells supplement brands anchored by hemp-derived cannabinoids and functional ingredients. The company offers CBD oils, gummies, capsules, topicals, and hemp-derived Delta-9 THC products under its flagship cbdMD brand, pet wellness products under Paw CBD, functional mushroom formulations under ATRX, and hemp-derived THC-infused beverages under Oasis. Products are distributed through direct-to-consumer e-commerce platforms, online marketplaces, wholesale retailers, specialty health channels, and international markets.
Summary from 10-K filed 2025-12-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Sales | 19 | 20 | 25 | 37 | 47 | |
| Allowances | −210 | −440,152 | −898,495 | −2 | −3 | |
| Total Net Sales | 19 | 19 | 24 | 35 | 44 | |
| Cost of sales | 7 | 7 | 9 | 13 | 14 | |
| Gross Profit | 12 | 12 | 15 | 22 | 30 | |
| Operating expenses | 14 | 15 | 24 | 40 | 50 | |
| Loss from operations | −2 | −3 | −22 | −78 | −20 | |
| Decrease of contingent liability | 0 | 74,580 | 185,638 | 8 | −7 | |
| Increase in fair value of convertible debt | 87,380 | −429,789 | 0 | — | — | |
| Interest income (expense) | 34,308 | −29,507 | 63,702 | 16,246 | −28,930 | |
| Loss before provision for income taxes | −2 | −4 | −23 | −70 | −24 | |
| Benefit (expense) for income taxes | 0 | 0 | 0 | 0 | 895,000 | |
| Net Loss | −2 | −4 | −23 | −70 | −23 | |
| Preferred dividends | 2 | 4 | 4 | 4 | 3 | |
| Net Loss attributable to common shareholders | −4 | −8 | −27 | −74 | −26 | |
| Basic and Diluted earnings per share (in dollars per share) | −1.09 | −14.29 | −13.32 | −55.8 | −0.47 | |
| Weighted average number of shares Basic and Diluted: (in shares) | 4 | 539,069 | 2 | 1 | 55 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2024 2024-06-30 | FY 2024 2024-03-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 2 | — | — | — | |
| Accounts receivable, net | 1 | 983,910 | — | — | — | |
| Inventory, net | 3 | 2 | — | — | — | |
| Inventory prepaid | 214,795 | 159,006 | — | — | — | |
| Prepaid sponsorship | 25,231 | 21,754 | — | — | — | |
| Prepaid expenses and other current assets | 277,147 | 406,674 | — | — | — | |
| Total current assets | 7 | 6 | — | — | — | |
| Property and equipment, net | 277,377 | 454,268 | — | — | — | |
| Operating lease assets | 703,934 | 85,817 | — | — | — | |
| Deposits for facilities | 62,708 | 62,708 | — | — | — | |
| Intangible assets, net | 2 | 3 | — | — | — | |
| Investment in other securities, noncurrent | 700,000 | 700,000 | — | — | — | |
| Total other assets | 4 | 4 | — | — | — | |
| Total assets | 10 | 11 | — | — | — | |
| Accounts payable | 1 | 2 | — | — | — | |
| Accrued expenses | 735,672 | 632,674 | — | — | — | |
| Accrued dividends | 0 | 5 | — | — | — | |
| Deferred Revenue | 506,289 | 503,254 | — | — | — | |
| Operating leases current portion | 778,240 | 98,696 | — | — | — | |
| Convertible notes, at fair value | — | 1 | — | — | — | |
| Total current liabilities | 3 | 9 | — | — | — | |
| Operating leases - long term portion | 0 | 0 | — | — | — | |
| Total long term liabilities | 0 | 0 | — | — | — | |
| Total liabilities | 3 | 9 | — | — | — | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock, authorized 50,000,000 shares, $0.001 par value, 1,700,000 and 5,000,000 shares issued and outstanding, respectively | 1,700 | 5,000 | — | — | — | |
| Common stock, authorized 150,000,000 shares, $0.001 par value, 8,917,054 and 492,383 shares issued and outstanding, respectively | 8,917 | 492 | — | — | — | |
| Additional paid in capital | 187 | 184 | — | — | — | |
| Comprehensive other expense | 0 | −7,189 | — | — | — | |
| Accumulated deficit | −179 | −182 | — | — | — | |
| Total cbdMD, Inc. shareholders' equity | 7 | 2 | 3 | 3 | 7 | |
| Total liabilities and shareholders' equity | 10 | 11 | — | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Stock based compensation | 0 | 5,015 | 233,666 | 555,215 | 1 | |
| Restricted stock expense | 14,121 | 11,885 | 109,202 | 373,610 | 2 | |
| Issuance of stock for services | 86,657 | 0 | — | 0 | 97,720 | |
| Inventory and materials impairment | 365,979 | 921,314 | 175,499 | 878,142 | 670,580 | |
| Intangibles amortization | 765,078 | 697,510 | 1 | 884,380 | 0 | |
| Depreciation | 361,063 | 452,326 | 404,280 | 948,962 | 1 | |
| Credit losses | 382,588 | 54,322 | — | — | — | |
| Gain on termination of operating lease | 0 | 696,280 | — | — | — | |
| Amortization of operating lease asset | 669,781 | 670,621 | 1 | 1 | 1 | |
| Accounts receivable | −439,565 | 177,858 | 278,482 | 65,541 | −183,735 | |
| Deposits | 0 | 76,000 | 105,898 | 284,977 | 261,125 | |
| Inventory | −732,919 | 766,472 | 27,443 | −112,189 | −1 | |
| Prepaid inventory | −55,789 | 23,670 | 328,784 | 40,060 | −263,341 | |
| Prepaid expenses and other current assets | 126,051 | 396,311 | 2 | −289,586 | 525,670 | |
| Accounts payable and accrued expenses | −261,883 | −1 | −1 | −2 | −104,422 | |
| Operating lease liability | −608,354 | −1 | −1 | −1 | −1 | |
| Deferred revenue / customer deposits | 3,099 | 318,008 | 203,341 | 203,341 | 3,723 | |
| Cash used by operating activities | −1 | −352,792 | −4 | −15 | −14 | |
| Purchase of intangible assets | 0 | −100,000 | 0 | 0 | −2 | |
| Purchase of property and equipment | −184,172 | −190,015 | −297,549 | −688,680 | −342,013 | |
| Cash used by investing activities | −184,172 | −290,015 | 702,451 | −688,680 | −3 | |
| Proceeds from issuance of common stock | 0 | 50,001 | 2 | 0 | 0 | |
| Note payable | 0 | 1 | −132,599 | −33,355 | −151,551 | |
| Proceeds from issuance of preferred stock | 1 | 0 | — | 0 | 31 | |
| Cash provided by financing activities | 1 | 1 | −1 | −4 | 28 | |
| Net (decrease) increase in cash | −191,311 | 654,693 | −5 | −20 | 12 | |
| Interest expense | — | 74,638 | 6,399 | 2,364 | 2,364 | |
| Issuance of shares for conversion of debt and accrued interest | 1 | 515,601 | 0 | — | — | |
| Change in lease asset related to extinguishment of HQ lease and new warehouse lease | −2 | 0 | — | — | — | |
| Issuance of shares for intangible asset | 0 | 40,725 | 0 | — | — | |
| Preferred dividends accrued but not paid | 2 | 4 | 667,000 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is cbdMD, Inc.'s CIK number?
cbdMD, Inc.'s SEC CIK number is 0001644903 (1644903). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find cbdMD, Inc.'s SEC filings?
All of cbdMD, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did cbdMD, Inc. last report earnings?
cbdMD, Inc. (YCBD) most recently filed an earnings 8-K with the SEC on Nov 25, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-25-036342). This is cbdMD, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is cbdMD, Inc.'s most recent earnings 8-K?
cbdMD, Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 25, 2025 under accession 0001437749-25-036342. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View cbdMD, Inc.'s latest earnings 8-K →
Look up any company's CIK number →